Literature DB >> 35925390

TIMP3::ALK fusions characterize a distinctive myxoid fibroblastic tumor of the vocal cords: a report of 7 cases.

Natálie Klubíčková1,2, Michael Michal3,4, Abbas Agaimy5, Nina Zidar6, Michal Pavlovský7, Kenji Yorita8, Petr Grossmann4, Veronika Hájková4, Nikola Ptáková4, Petr Šteiner4, Michal Michal3,4.   

Abstract

We report 7 cases of an indolent, variably myxoid tumor of the vocal cords, characterized by overt cellular atypia with large cells containing intranuclear and intracytoplasmic vacuoles, delicate curvilinear vessels, and sparse inflammatory infiltrate. Six patients were male, aged 15 to 65 years, and 1 patient was a 54-year-old female. All tumors were located in the superficial portion of the vocal cord. One patient suffered a recurrence that was completely resected; all patients with available follow-up data currently have no evidence of disease. The tumors contained alternating areas with myxoid stroma and more compacted regions with tumor cells organized in short fascicles, interwoven with delicate curvilinear vasculature. Overt cellular atypia with large cells containing intranuclear and intracytoplasmic vacuoles or resembling ganglion cells was present in all cases but mitoses and necrosis were absent. ALK immunostaining was positive in all cases, while most tumors were negative for smooth muscle actin. Targeted RNA-sequencing revealed an identical TIMP3::ALK fusion with exon 1 of TIMP3 gene being fused with exon 12 of ALK gene in all analyzable cases. For various reasons discussed, it remains unclear whether this tumor represents a mere subtype of IMT or a separate entity. Nevertheless, it is a morphologically distinct and diagnostically challenging lesion that needs to be recognized by surgical pathologists in order to prevent overdiagnosis in this clinically very delicate area.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Inflammatory myofibroblastic tumor; Larynx; Myxoid fibroblastic tumor; Soft tissues; TIMP3::ALK; Vocal cords

Year:  2022        PMID: 35925390     DOI: 10.1007/s00428-022-03389-2

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.535


  39 in total

1.  Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement.

Authors:  Cristina R Antonescu; Albert J H Suurmeijer; Lei Zhang; Yun-Shao Sung; Achim A Jungbluth; William D Travis; Hikmat Al-Ahmadie; Christopher D M Fletcher; Rita Alaggio
Journal:  Am J Surg Pathol       Date:  2015-07       Impact factor: 6.394

2.  Polypoid laryngeal inflammatory myofibroblastic tumors: misleading lesions: description of six cases showing ALK overexpression.

Authors:  Clémence Pierry; Gaëlle Pérot; Marie Karanian-Philippe; Agnès Neuville; Anne Gomez-Brouchet; Sabine Crestani; Jean-Michel Coindre
Journal:  Am J Clin Pathol       Date:  2015-09       Impact factor: 2.493

3.  ALK Rearrangements Characterize 2 Distinct Types of Salivary Gland Carcinomas: Clinicopathologic and Molecular Analysis of 4 Cases and Literature Review.

Authors:  Abbas Agaimy; Martina Baněčková; Stephan Ihrler; Sarina K Mueller; Alessandro Franchi; Arndt Hartmann; Robert Stoehr; Alena Skálová
Journal:  Am J Surg Pathol       Date:  2021-03-22       Impact factor: 6.394

Review 4.  Extrapulmonary inflammatory myofibroblastic tumor: a clinical and pathological survey.

Authors:  C M Coffin; P A Humphrey; L P Dehner
Journal:  Semin Diagn Pathol       Date:  1998-05       Impact factor: 3.464

5.  Immunohistochemical and selected genetic reflex testing of all uterine leiomyosarcomas and STUMPs for ALK gene rearrangement may provide an effective screening tool in identifying uterine ALK-rearranged mesenchymal tumors.

Authors:  Nikola Ptáková; Markéta Miesbauerová; Ján Kosťun; Petr Grossmann; Henrieta Šidlová; Jaroslav Pavelka; Jiří Presl; Reza Alaghehbandan; Jiří Bouda; Ondrej Ondič
Journal:  Virchows Arch       Date:  2018-08-16       Impact factor: 4.064

6.  Clinicopathologic and Genomic Characterization of Inflammatory Myofibroblastic Tumors of the Head and Neck: Highlighting a Novel Fusion and Potential Diagnostic Pitfall.

Authors:  Darcy A Kerr; Lester D R Thompson; Laura J Tafe; Vickie Y Jo; Azfar Neyaz; Prashanthi Divakar; Joseph A Paydarfar; David A Pastel; Keisuke Shirai; Ivy John; Raja R Seethala; Claudia M Salgado; Vikram Deshpande; Julia A Bridge; Karl Kashofer; Iva Brčić; Konstantinos Linos
Journal:  Am J Surg Pathol       Date:  2021-05-18       Impact factor: 6.394

7.  Vocal cord inflammatory myofibroblastic tumor with mucoid deposits harboring TIMP3-ALK fusion: A potential diagnostic pitfall.

Authors:  Kenji Yorita; Yuki Togashi; Hideyuki Nakagawa; Katsushi Miyazaki; Seiji Sakata; Satoko Baba; Kengo Takeuchi; Yoshihiro Hayashi; Ichiro Murakami; Naoto Kuroda; Yoshinao Oda; Kenichi Kohashi; Yuichi Yamada; Daisuke Kiyozawa; Michael Michal; Michal Michal
Journal:  Pathol Int       Date:  2019-06-18       Impact factor: 2.534

8.  Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinicopathologic and immunohistochemical study of 84 cases.

Authors:  C M Coffin; J Watterson; J R Priest; L P Dehner
Journal:  Am J Surg Pathol       Date:  1995-08       Impact factor: 6.394

9.  ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours.

Authors:  Hidetaka Yamamoto; Akihiko Yoshida; Kenichi Taguchi; Kenichi Kohashi; Yui Hatanaka; Atsushi Yamashita; Daisuke Mori; Yoshinao Oda
Journal:  Histopathology       Date:  2016-01-19       Impact factor: 5.087

10.  Inflammatory fibrosarcoma of the mesentery and retroperitoneum. A tumor closely simulating inflammatory pseudotumor.

Authors:  J M Meis; F M Enzinger
Journal:  Am J Surg Pathol       Date:  1991-12       Impact factor: 6.394

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.